BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 12654440)

  • 1. Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas.
    Chen C; Shu HK; Goldwein JW; Womer RB; Maity A
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1294-9. PubMed ID: 12654440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parameningeal rhabdomyosarcoma: outcomes and opportunities.
    Yang JC; Wexler LH; Meyers PA; Wolden SL
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e61-6. PubMed ID: 23021437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-Dose Cyclophosphamide.
    Casey DL; Wexler LH; Wolden SL
    Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1151-1157. PubMed ID: 30508617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The challenging role of radiation therapy for very young children with rhabdomyosarcoma.
    Puri DR; Wexler LH; Meyers PA; La Quaglia MP; Healey JH; Wolden SL
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1177-84. PubMed ID: 16682130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed radiotherapy following dose intensive chemotherapy for parameningeal rhabdomyosarcoma (PM-RMS) of childhood.
    Douglas JG; Arndt CA; Hawkins DS
    Eur J Cancer; 2007 Apr; 43(6):1045-50. PubMed ID: 17368885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma.
    Buszek SM; Ludmir EB; Grosshans DR; McAleer MF; McGovern SL; Harrison DJ; Okcu MF; Chintagumpala MM; Mahajan A; Paulino AC
    Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):718-725. PubMed ID: 33516439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity-modulated radiotherapy with use of cone-down boost for pediatric head-and-neck rhabdomyosarcoma.
    McDonald MW; Esiashvili N; George BA; Katzenstein HM; Olson TA; Rapkin LB; Marcus RB
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):884-91. PubMed ID: 18455321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV.
    Baker KS; Anderson JR; Link MP; Grier HE; Qualman SJ; Maurer HM; Breneman JC; Wiener ES; Crist WM
    J Clin Oncol; 2000 Jun; 18(12):2427-34. PubMed ID: 10856103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rhabdomyosarcoma in middle to old-aged patients: analysis of clinicopathological features and prognosis in 76 cases].
    Yu L; Wang J
    Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):910-6. PubMed ID: 23336377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of failure and toxicity profile following proton beam therapy for pediatric bladder and prostate rhabdomyosarcoma.
    Buszek SM; Ludmir EB; Grosshans DR; McAleer MF; McGovern SL; Harrison DJ; Okcu MF; Chintagumpala MM; Mahajan A; Paulino AC
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27952. PubMed ID: 31397065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.
    Wolden SL; Lyden ER; Arndt CA; Hawkins DS; Anderson JR; Rodeberg DA; Morris CD; Donaldson SS
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1071-6. PubMed ID: 26581144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Orbital rhabdomyosarcoma: difficulties with European treatment protocol].
    Olivier Pascual N; Calvo JM; Abelairas Gómez JM
    Arch Soc Esp Oftalmol; 2005 Jun; 80(6):331-8. PubMed ID: 15986273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects.
    Childs SK; Kozak KR; Friedmann AM; Yeap BY; Adams J; MacDonald SM; Liebsch NJ; Tarbell NJ; Yock TI
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):635-42. PubMed ID: 21377294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Raney RB; Walterhouse DO; Meza JL; Andrassy RJ; Breneman JC; Crist WM; Maurer HM; Meyer WH; Parham DM; Anderson JR
    J Clin Oncol; 2011 Apr; 29(10):1312-8. PubMed ID: 21357783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
    Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84.
    Flamant F; Rodary C; Rey A; Praquin MT; Sommelet D; Quintana E; Theobald S; Brunat-Mentigny M; Otten J; Voûte PA; Habrand JL; Martelli H; Barrett A; Terrier-Lacombe MJ; Oberlin O
    Eur J Cancer; 1998 Jun; 34(7):1050-62. PubMed ID: 9849454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.
    Breneman J; Meza J; Donaldson SS; Raney RB; Wolden S; Michalski J; Laurie F; Rodeberg DA; Meyer W; Walterhouse D; Hawkins DS
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):720-6. PubMed ID: 22104356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
    Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
    J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brachytherapy as part of the multidisciplinary treatment of childhood rhabdomyosarcomas of the orbit.
    Blank LE; Koedooder K; van der Grient HN; Wolffs NA; van de Kar M; Merks JH; Pieters BR; Saeed P; Baldeschi L; Freling NJ; Koning CC
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1463-9. PubMed ID: 19864080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
    Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.